Trial · NCT07187765
Respiratory Safety of Oliceridine During Sedated Gastrointestinal Endoscopy
NCT07187765, Not applicable, Completed, Shiyou Wei
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Respiratory Safety of Oliceridine During Sedated Gastrointestinal Endoscopy. Trials, record NCT07187765. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07187765
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Respiratory Safety of Oliceridine During Sedated Gastrointestinal Endoscopy
- NCT number
- NCT07187765
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 508 participants, actual
- Lead sponsor
- Shiyou Wei
- Conditions
- Hypoxemia During Surgery, Gastrointestinal Endoscopy
- Interventions
- Oliceridine, Sufentanil
- First posted
- 2025-09-23
- Last updated
- 2026-09-04
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Hypoxemia (SpO₂ ≤92%) During Sedation for Gastrointestinal Endoscopy | From the start of sedation to the end of the gastrointestinal endoscopic procedure (approximately 1-60 minutes) | The proportion of participants who experience hypoxemia, defined as a peripheral oxygen saturation (SpO₂) ≤92%, at any time from the start of sedation until the end of the endoscopic procedure. |
| Secondary | Incidence of secondary hypoxemic events during sedation for gastrointestinal endoscopy | From the start of sedation to the end of the gastrointestinal endoscopic procedure (approximately 1-60 minutes) | The proportion of participants who experience any of the following between the start of sedation and the end of the endoscopic procedure : 1. Severe hypoxemia, defined as lowest SpO₂ ≤ 85% 2. A drop in SpO₂ of ≥ 5% relative to the participant's highest measured value during the sedation period |
| Other | Number of participants requiring hypoxemia rescue interventions | From the start of sedation to the end of the gastrointestinal endoscopic procedure (approximately 1-60 minutes) | Number of participants who, during sedation, required one or more of the following airway/ventilatory rescue measures to treat hypoxemia: none, mask ventilation, jaw-thrust maneuver, tracheal intubation, or other. |
| Other | Total propofol dose administered | From the start of sedation to the end of the gastrointestinal endoscopic procedure (approximately 1-60 minutes) | Cumulative amount of propofol (in mg) administered intravenously to each participant for sedation during the endoscopic procedure. |
| Other | Incidence of opioid-related adverse events within 1 hour post-procedure | 1 hour after endoscopic procedure | Proportion of participants experiencing any of the following within the first hour after procedure completion: nausea, vomiting, hypoxemia, pruritus, or dizziness. |
| Other | Incidence of intra-procedural anesthesia-related adverse events | From initiation of sedation to completion of endoscopic procedure | Proportion of participants who, during sedation, experienced any of: procedure interruption due to anesthesia (e.g. patient movement, hypoxemia), bradycardia, tachycardia, hypotension, hypertension, or required administration of vasoactive medications (vasopressors or chronotropes). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07187765
GET https://conductscience.org/api/trials/v1/NCT07187765/registered